Montaner-Angoiti Esperanza, Marín-García Pablo Jesús, Llobat Lola
Departamento Producción y Sanidad Animal, Salud Pública y Ciencia y Tecnología de los Alimentos, Facultad de Veterinaria, Universidad Cardenal Herrera-CEU, CEU Universities, 46115 Valencia, Spain.
Animals (Basel). 2023 Jan 29;13(3):468. doi: 10.3390/ani13030468.
Canine malignant lymphoma is a common neoplasia in dogs, and some studies have used dogs as a research model for molecular mechanisms of lymphomas in humans. In two species, chemotherapy is the treatment of choice, but the resistance to conventional anticancer drugs is frequent. The knowledge of molecular mechanisms of development and progression of neoplasia has expanded in recent years, and the underlying epigenetic mechanisms are increasingly well known. These studies open up new ways of discovering therapeutic biomarkers. Histone deacetylases and demethylase inhibitors could be a future treatment for canine lymphoma, and the use of microRNAs as diagnosis and prognosis biomarkers is getting closer. This review summarises the epigenetic mechanisms underlying canine lymphoma and their possible application as treatment and biomarkers, both prognostic and diagnostic.
犬恶性淋巴瘤是犬类常见的肿瘤，一些研究已将犬用作人类淋巴瘤分子机制的研究模型。在这两个物种中，化疗是首选治疗方法，但对传统抗癌药物产生耐药性的情况很常见。近年来，关于肿瘤发生和发展分子机制的知识不断扩展，其潜在的表观遗传机制也越来越为人所知。这些研究开辟了发现治疗性生物标志物的新途径。组蛋白去乙酰化酶和去甲基化酶抑制剂可能成为未来治疗犬淋巴瘤的方法，并且将微小RNA用作诊断和预后生物标志物也越来越近了。这篇综述总结了犬淋巴瘤潜在的表观遗传机制及其作为治疗方法和生物标志物（包括预后和诊断方面）的可能应用。
